EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 283 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Longer Duration of Treatment with ICIs Associated with a Higher Rate... March 5, 2025 EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib August 16, 2024 Nurse Who Battled Cancer While In School Surprises Her Dad With... March 1, 2021 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... March 26, 2019 Load more HOT NEWS EMA Recommends Extension of Indications for Lorlatinib Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia The most important cancer research stories of 2022 Study Finds Light Therapy Helps Radiation-Related Skin Damage Heal 50% Faster
